VBL Therapeutics (Nasdaq: VBLT) will present positive interim data from a
Phase 1/2 clinical trial of its platinum-resistant Mullerian cancer
treatment VB-111. The stock price leaped $1.70 to $5.78.
VBL Therapeutics to present data
May 14, 2015 at 13:11 PM EDT
